ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Price Down 4.7% – What’s Next?

ChronoScale Corporation Common Stock (NASDAQ:CHRN) traded down 4.7% during trading on Monday. The company traded as low as $15.15 and last traded at $15.30. Approximately 3,335 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 227,400 shares. The stock had previously closed at $16.05.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CHRN. Weiss Ratings raised ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, October 9th. Compass Point assumed coverage on ChronoScale Corporation Common Stock in a report on Friday, October 16th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Northland Securities initiated coverage on shares of ChronoScale Corporation Common Stock in a research report on Friday, September 18th. They set an “outperform” rating and a $32.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, ChronoScale Corporation Common Stock currently has a consensus rating of “Hold” and an average price target of $21.00.

ChronoScale Corporation Common Stock Price Performance

The company has a current ratio of 0.30, a quick ratio of 0.30 and a debt-to-equity ratio of 0.02. The stock has a fifty day simple moving average of $19.62 and a 200-day simple moving average of $18.29. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -3.65 and a beta of 0.98.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last posted its quarterly earnings results on Wednesday, October 14th. The company reported ($0.29) earnings per share (EPS) for the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 66.16% and a negative net margin of 135.66%. The company had revenue of $41.48 million during the quarter. As a group, equities research analysts expect that ChronoScale Corporation Common Stock will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc grew its stake in ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,338 shares of the company’s stock after acquiring an additional 1,195 shares during the period. Roble Belko & Company Inc owned 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent filing with the Securities and Exchange Commission. 6.42% of the stock is currently owned by institutional investors.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.